Chemotherapy Effect, Gastric Cancer, Predictive Cancer Model
Conditions
Keywords
gastric cancer, RNA sequencing, chemotherapy response, miRNA sequencing
Brief summary
* discovery and validation of biomarker predicting gastric cancer chemotherapy response * Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response * Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response * Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort * Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response
Detailed description
* discovery and validation of biomarker predicting gastric cancer chemotherapy response * Analysis for expression level of mRNA in fresh frozen gastric cancer tissue by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group Palliative chemotherapy (inoperable patients) * institutional primary Chemotherapy regimen (XP or Xelox) 1. response group 2. progression group Post-OP adjuvant chemotherapy * institutional primary Chemotherapy regimen 1. complete response group 2. non-responder group <!-- --> 1. and 2) groups: age, sex, regimen matched * Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group * the same patients in mRNA sequencing * Validation of mRNA and miRNA in multiple independent cohort method of measurement of RNA expression: qRT-PCR * Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response combination of biologic biomarker and clinical factors to predict the chemotherapy response in gastric cancer
Interventions
DRUGChemotherapy
Institutinal standard chemotherapy as first line : XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin
Sponsors
Kyungpook National University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* new gastric cancer patients who has scheduled to start 1st cycle of chemotherapy * patients who agreed this study and voluntarily assigned the informed consents.
Exclusion criteria
* patients who refused the study. * patients who have other cancers * heavy alcoholics
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Discovery of predicting bio-markers for gastric cancer chemotherapy response | up to 36 months | Discovery of predicting bio-markers for gastric cancer chemotherapy response using next generation sequencing and qRT-PCR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Combination prediction model for adjuvant chemotherapy response in gastric cancer | up to 5 years | Combination prediction model of biologic biomarkers and clinical factors for the response of adjuvant chemotherapy in gastric cancer |
| Combination prediction model for palliative chemotherapy response in gastric cancer | up to 3 years | Combination prediction model of biologic biomarkers and clinical factors for the response of palliative chemotherapy in gastric cancer |
Countries
South Korea
Contacts
Primary ContactSu Youn Nam, MD, PhD
Outcome results
None listed